What is the full potential of baricitinib in treating patients with COVID-19?

Biddle, Kathryn; White, Jonathan; Sofat, Nidhi

Biddle, Kathryn; White, Jonathan; Sofat, Nidhi.

Biddle K; General Medicine, St George's University Hospitals NHS Foundation Trust, London, UK.
White J; Institute for Infection & Immunity, St George's, University of London and Department of Rheumatology, St George's University Hospitals NHS Foundation Trust, London, UK.
Sofat N; General Medicine, St George's University Hospitals NHS Foundation Trust, London, UK.

Expert Rev Clin Immunol ; 18(6): 545-549, 2022 06.

Article in English | MEDLINE | ID: covidwho-1830433

Subject(s)

Azetidines; COVID-19 Drug Treatment; Azetidines/therapeutic use; Humans; Purines/therapeutic use; Pyrazoles; Sulfonamides

Keywords

Baricitinib; COVID-19; Janus-kinase inhibitors; SARS-CoV-2; immunomodulation

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Azetidines / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Expert Rev Clin Immunol Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: 1744666X.2022.2072298

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google